Marcel CPA - Altamira Therapeutics Chief Officer
Insider
Marcel CPA is Chief Officer of Altamira Therapeutics
| Age | 67 |
| Phone | 441 295 5950 |
| Web | https://altamiratherapeutics.com |
Altamira Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5715) % which means that it has lost $0.5715 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6878) %, meaning that it created substantial loss on money invested by shareholders. Altamira Therapeutics' management efficiency ratios could be used to measure how well Altamira Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Altamira Therapeutics currently holds 99.66 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Altamira Therapeutics has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Altamira Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ibrahim MD | Enveric Biosciences | 55 | |
| MBA MD | Immix Biopharma | 49 | |
| MBA IV | Enveric Biosciences | 68 | |
| DSc MSE | Immix Biopharma | 75 | |
| Joseph Tucker | Enveric Biosciences | 56 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Pamela MBA | Pyxis Oncology | 63 | |
| Donald Picker | Cns Pharmaceuticals | 79 | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Jan Pinkas | Pyxis Oncology | N/A | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Balu Balasubramanian | Pyxis Oncology | N/A | |
| Karen Cashmere | ZyVersa Therapeutics | 73 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Valerie MD | Elevation Oncology | 47 | |
| MD FAAAAI | Palisade Bio | N/A | |
| Nandan BS | Immix Biopharma | 63 | |
| Peter Facchini | Enveric Biosciences | 61 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| Joseph Ferra | Elevation Oncology | 50 | |
Management Performance
| Return On Equity | -3.69 | |||
| Return On Asset | -0.57 |
Altamira Therapeutics Leadership Team
Elected by the shareholders, the Altamira Therapeutics' board of directors comprises two types of representatives: Altamira Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Altamira. The board's role is to monitor Altamira Therapeutics' management team and ensure that shareholders' interests are well served. Altamira Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Altamira Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Covadonga Paeda, Chief Officer | ||
| Covadonga Paneda, Chief Officer | ||
| Jean Lechance, Unit Bus | ||
| Thomas Meyer, President, Founder | ||
| Samuel MD, Chief Officer | ||
| Marcel CPA, Chief Officer |
Altamira Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Altamira Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.69 | |||
| Return On Asset | -0.57 | |||
| Current Valuation | 860.75 K | |||
| Shares Outstanding | 3.78 M | |||
| Shares Owned By Insiders | 0.52 % | |||
| Shares Owned By Institutions | 3.13 % | |||
| Number Of Shares Shorted | 50.63 K | |||
| Price To Book | 0.08 X | |||
| Price To Sales | 0.64 X | |||
| Gross Profit | (2.18 M) |
Pair Trading with Altamira Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altamira Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altamira Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Roper Technologies, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Roper Technologies, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Roper Technologies, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Roper Technologies, to buy it.
The correlation of Roper Technologies, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Roper Technologies, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Roper Technologies, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Roper Technologies, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Altamira Stock
If you are still planning to invest in Altamira Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Altamira Therapeutics' history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |